Wiegand Gesa, Sieverding Ludger, Bocksch Wolfgang, Hofbeck Michael
Department of Pediatric Cardiology, University Children's Hospital, Hoppe-Seyler-Strasse 1, 72076, Tuebingen, Germany,
Pediatr Cardiol. 2013 Oct;34(7):1668-73. doi: 10.1007/s00246-013-0701-9. Epub 2013 Apr 17.
Although vascular plugs allow the interventional closure of medium-sized to large abnormal vessels, their application is limited by the need for long sheaths or large guiding catheters. The authors report their experience with the new Amplatzer vascular plug 4 (AVP 4), a self-expanding spindle-shaped occluder made of Nitinol wire mash, which can be placed through 4-Fr catheters with an internal diameter of 0.038 in. or larger. From October 2009 until June 2012, 14 AVP 4 devices were deployed in 12 patients (ages, 0.3-48.8 years). Nine patients had venovenous or arteriovenous collaterals in functional univentricular hearts. One patient had pulmonary atresia with a ventricular septal defect and major aortopulmonary collateral arteries, and one patient had a pulmonary arteriovenous fistula. One child had a large coronary artery fistula to the right atrium. The authors used AVP 4 devices with diameters of 4-8 mm. In all the patients, the AVP 4 was implanted successfully. No occluder dislocations and no complications related to the procedure occurred. Complete vessel occlusion was achieved in seven cases. In seven additional cases, a residual shunt was present at the end of the procedure while the patients were still fully heparinized. In 2 of 14 vessels, the decision was made to place additional devices to abolish residual shunting. According to the authors' experience, the AVP 4 allows safe and effective occlusion of medium-size and large abnormal vessels. It is also well suited for tortuous high-flow vessels such as coronary or pulmonary arteriovenous fistulas. In case of a suboptimal position, it is possible to reposition the occluder with ease. Further studies are needed to determine whether initial residual shunting in heparinized patients disappears during follow-up care. The AVP 4 represents a valuable new device for the interventional treatment of complex congenital vessel malformations.
尽管血管封堵器可用于介入封堵中大型异常血管,但其应用受限于需要长鞘管或大型引导导管。作者报告了他们使用新型Amplatzer血管封堵器4(AVP 4)的经验,这是一种由镍钛诺金属丝网制成的自膨胀纺锤形封堵器,可通过内径为0.038英寸或更大的4F导管置入。从2009年10月至2012年6月,14个AVP 4装置被应用于12例患者(年龄0.3 - 48.8岁)。9例患者在功能性单心室心脏中有静脉 - 静脉或动脉 - 静脉侧支血管。1例患者患有室间隔缺损合并肺动脉闭锁及主要的主肺动脉侧支动脉,1例患者患有肺动静脉瘘。1名儿童有一条粗大的冠状动脉瘘通向右心房。作者使用了直径为4 - 8mm的AVP 4装置。所有患者中,AVP 4均成功植入。未发生封堵器脱位及与手术相关的并发症。7例实现了血管完全闭塞。另外7例在手术结束时患者仍处于充分肝素化状态时有残余分流。在14条血管中的2条血管中,决定放置额外的装置以消除残余分流。根据作者的经验,AVP 4可安全有效地封堵中大型异常血管。它也非常适合于如冠状动脉或肺动静脉瘘等迂曲的高流量血管。在位置不理想的情况下,可以轻松重新定位封堵器。需要进一步研究以确定肝素化患者最初的残余分流在随访期间是否消失。AVP 4是用于复杂先天性血管畸形介入治疗的一种有价值的新装置。